All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

How does the prognostic outlook for patients with double-hit lymphoma impact disease management?

Nov 21, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in lymphoma.

During the COLYM 2022 Annual Meeting, the Lymphoma Hub spoke with Narendranath Epperla, The Ohio State University, Columbus, US. We asked, How does the prognostic outlook for patients with double-hit lymphoma impact disease management?

How does the prognostic outlook for patients with double-hit lymphoma impact disease management?

Narendranath starts by defining double-hit lymphoma, explaining that patients with this classification are often refractory to the standard-of care front-line treatment R-CHOP. Narendranath then discusses outcome data for patients receiving dose-adjusted R-EPOCH, the typical front-line treatment for double- and triple-hit lymphoma.

Narendranath goes on to addresses the potential of more effective treatments than dose-adjusted R-EPOCH for these patients, reviewing studies that have evaluated the efficacy and toxicity of lenalidomide combined with R-CHOP, R-EPOCH, and dose-adjusted R-EPOCH. Promising results from early phase studies investigating other approaches, such as venetoclax combined with dose-adjusted R-EPOCH and CAR T-cell therapy, are also discussed.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you